Adaptimmune Therapeutics Plc Stock Today
| ADAP Stock | USD 0.84 0.03 3.45% |
Performance0 of 100
| Odds Of DistressOver 51
|
Adaptimmune Therapeutics is selling at 0.84 as of the 19th of October 2024; that is 3.45 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.84. Adaptimmune Therapeutics has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Adaptimmune Therapeutics Plc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of July 2024 and ending today, the 19th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of May 2015 | Category Healthcare | Classification Health Care |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. The company has 255.74 M outstanding shares of which 6.09 M shares are presently shorted by private and institutional investors with about 5.92 trading days to cover. More on Adaptimmune Therapeutics Plc
Moving together with Adaptimmune Stock
| 0.77 | VALN | Valneva SE ADR | PairCorr |
| 0.83 | DYAI | Dyadic International | PairCorr |
| 0.83 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Adaptimmune Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Adaptimmune Stock Highlights
| Principal CEO | Adrian Rawcliffe | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAdaptimmune Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adaptimmune Therapeutics' financial leverage. It provides some insight into what part of Adaptimmune Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adaptimmune Therapeutics Plc (ADAP) is traded on NASDAQ Exchange in USA. It is located in 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX and employs 449 people. Adaptimmune Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 215.52 M. Adaptimmune Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 255.74 M outstanding shares of which 6.09 M shares are presently shorted by private and institutional investors with about 5.92 trading days to cover.
Adaptimmune Therapeutics Plc currently holds about 199.67 M in cash with (141.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Adaptimmune Therapeutics Probability Of Bankruptcy
Ownership AllocationAdaptimmune Therapeutics holds a total of 255.74 Million outstanding shares. Over half of Adaptimmune Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Adaptimmune Ownership Details
Adaptimmune Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2024-06-30 | 1.8 M | |
| Tang Capital Management Llc | 2024-06-30 | 1.7 M | |
| Fmr Inc | 2024-06-30 | 1.7 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 1 M | |
| Millennium Management Llc | 2024-06-30 | 779.6 K | |
| Redmile Group, Llc | 2024-06-30 | 715.6 K | |
| Acuitas Investments, Llc | 2024-06-30 | 541.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 440.8 K | |
| Rathbone Brothers Plc | 2024-06-30 | 432.8 K | |
| Matrix Capital Management Company, Llc | 2024-06-30 | 39 M | |
| Ecor1 Capital, Llc | 2024-06-30 | 27.4 M |
Adaptimmune Therapeutics Historical Income Statement
Adaptimmune Stock Against Markets
Adaptimmune Therapeutics Corporate Management
| Kerry Sharp | Senior Council | Profile | |
| Dennis Williams | Senior Development | Profile | |
| Sbastien Desprez | VP Affairs | Profile | |
| Dana Lynch | Senior Communications | Profile | |
| Helen MBA | CoFounder Officer | Profile | |
| Bertrand Esq | Chief Officer | Profile |
Already Invested in Adaptimmune Therapeutics Plc?
The danger of trading Adaptimmune Therapeutics Plc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptimmune Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptimmune Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptimmune Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.